Novartis’ Enerzair Breezhaler (QVM149, IND/GLY/MF) Receives CHMP’s Recommendation for Approval as a Treatment for Uncontrolled Asthma

 Novartis’ Enerzair Breezhaler (QVM149, IND/GLY/MF) Receives CHMP’s Recommendation for Approval as a Treatment for Uncontrolled Asthma

Shots:

  • The CHMP’s recommendation is based on P-III IRIDIUM study assessing IND/GLY/MF (150/50/160 μg & 150/50/80 μg) vs IND/MF doses (150/320 μg & 150/160 μg) in 3,092 patients in a ratio (1:1:1) with uncontrolled asthma, as determined by pulmonary function testing and effects on asthma control
  • The P-III IRIDIUM study resulted in improvements in lung function and ACQ-7 score. Both the treatment showed improvement in symptoms @26wks. but 2EPs was not met. In the secondary analyses, therapy showed a reduction in mod.-to-sev. and sev. asthma exacerbation rate with high-dose IND/GLY/MF vs high-dose Sal/Flu
  • Novartis is working with multiple regulatory authorities, including Switzerland, Japan and Canada to bring IND/GLY/MF and IND/MF to patients. QVM149 will be administered via the dose confirming Breezhaler device, if approved, it will be the first asthma treatment that can be prescribed together with a digital companion with app and a sensor in the EU

Click here ­to­ read full press release/ article | Ref: Novartis | Image: StraitTimes

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post